North America Lung Cancer Screening Market Forecast to 2030

North America Lung Cancer Screening Market Forecast to 2030 – Regional Analysis – by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

Send Enquiry
Item ID: BMIRE00029064 Category: Tags: , ,

$2,100$3,500

Description

The North America lung cancer screening market is expected to grow from US$ 965.41 million in 2022 to US$ 1,811.48 million by 2030. It is estimated to grow at a CAGR of 8.2% from 2022 to 2030.
Increasing Government Support Fuel North America lung cancer screening market.

Lung cancer is among the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis for lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are encouraged to undergo routine testing to detect the formation of cancerous growth in their lungs. According to estimates by the American Cancer Society for lung cancer in the US for 2023, about 238,340 new lung cancer cases were registered; of these, 120,790 in women and 117,550 in men were reported. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

North America Lung Cancer Screening Market Overview

The North America, Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side effects of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

In North America, the US holds a significant share of the North America Lung Cancer Screening Market . The market growth in this country is primarily driven by the increasing incidence of lung cancer and government initiatives. Lung cancer is the second most common cancer in both men and women in the US. As per the American Cancer Society, Inc., as of 2023, approximately 238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer, and ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung Cancer accounts for 1 in 5 of all cancer death, making it a leading cause of cancer death in the US. These statistics include both small cell lung cancer and NSCLC. NSCLC is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. For all types of lung cancer in the US, the 5-year relative survival rate is 23%, and for NSCLC, the 5-year relative survival rate for men and women is 23% and 33%, respectively. In the US, screening for lung cancer is recommended with a test called a low-dose helical or spiral computed tomography (CT or CAT) scan. Preventive Services Task Force (USPSTF) recommends that people aged 50–80, with a history of smoking 20 pack years or more, or who have quit within the past 15 years should go through screening for lung cancer with low-dose CT scans each year. As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca are entering into a partnership to develop and implement person-centered and sustainable approaches to increase lung cancer screening in rural America through the “Rural Appalachian Lung Cancer Screening Initiative.” The cancer mortality rate in the Appalachian region, including all of West Virginia and parts of 12 other states, is 10% higher than that in the rest of the US. The aim of this initiative is to double the five-year survival rate for lung cancer. Such initiatives are contributing to the North America Lung Cancer Screening Market growth in the US.

North America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Screening Market Segmentation

The North America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the North America lung cancer screening market is segmented into non–small cell lung cancer (NSCLC), and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the North America lung cancer screening market in 2022.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the North America lung cancer screening market in 2022.

Based on age group, the North America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the North America lung cancer screening market in 2022.

Based on end user, the North America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the North America lung cancer screening market in 2022.

Based on country, the North America Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer screening market in 2022.
Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, LungLife AI, Inc, Intelerad Medical Systems, bioAffinity Technologies, Inc, and CSV Health are some of the leading companies operating in the North America lung cancer screening market.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

At 8.2% CAGR, the North America Lung Cancer Screening Market is speculated to be worth US$ 1,811.48 million by 2030, saysthe research team

According tothe research team’ Research, the North America lung cancer screening market was valued at US$ 965.41 million in 2022 and is expected to reach US$ 1,811.48 million by 2030, registering a CAGR of 8.2% from 2022 to 2030. Rising lung cancer incidences is the critical factor attributed to the North America lung cancer screening market.
One of the dominant trends in the market for lung cancer diagnostics is the use of cutting-edge technologies. Liquid biopsies and genomic profiling will become increasingly popular, allowing for the more accurate and non-invasive detection of cancer-related mutations and biomarkers. By analyzing complicated medical data and images, AI and machine learning will improve diagnostic accuracy and help radiologists spot indications to lung cancer. Additionally, multi-modal approaches that combine different diagnostic modalities for comparative assessment will receive more attention. These developments will result in earlier and more precise diagnoses of lung cancer, enabling prompt interventions and better patient outcomes.

On the contrary, high cost of lung cancer screening hampers the North America lung cancer screening market.

Based on cancer type, the North America lung cancer screening market is segmented into non–small cell lung cancer (NSCLC) and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 81.8% share of North America lung cancer screening market in 2022, amassing US$ 789.70 million. It is projected to garner US$ 1,460.35 million by 2030 to expand at 8.0% CAGR during 2022–2030.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. The low dose computed tomography (LDCT) segment held 52.4% share of North America lung cancer screening market in 2022, amassing US$ 505.81 million. It is projected to garner US$ 981.55 million by 2030 to expand at 8.6% CAGR during 2022–2030.

Based on age group, the North America lung cancer screening market is segmented into 50 and older and below 50. The 50 and older segment held 89.9% share of North America lung cancer screening market in 2022, amassing US$ 868.34 million. It is projected to garner US$ 1,618.33 million by 2030 to expand at 8.1% CAGR during 2022–2030.

Based on end user, the North America lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 46.1% share of North America lung cancer screening market in 2022, amassing US$ 444.95 million. It is projected to garner US$ 807.02 million by 2030 to expand at 7.7% CAGR during 2022–2030.

Based on country, the North America lung cancer screening market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 92.6% share of North America lung cancer screening market in 2022. It was assessed at US$ 894.23 million in 2022 and is likely to hit US$ 1,687.93 million by 2030, exhibiting a CAGR of 8.3% during 2022–2030.
Key players operating the North America lung cancer screening market are Intelerad Medical Systems, Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, Siemens AG, bioAffinity Technologies, Inc, CVS Health, and Lunglife AI Inc, among others.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table of Contents

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Lung Cancer Screening Market – by Technology
1.3.2 North America Lung Cancer Screening Market – by Cancer Type
1.3.3 North America Lung Cancer Screening Market – by Age Group
1.3.4 North America Lung Cancer Screening Market – by End User
1.3.5 North America Lung Cancer Screening Market – by Country
2. North America Lung Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Lung Cancer Screening Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. North America Lung Cancer Screening Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Lung Cancer Incidences
5.1.2 Increasing Government Support
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
5.4.1 Use of Cutting-Edge Technologies
5.5 Impact Analysis
6. Lung Cancer Screening Market – North America Analysis
6.1 North America Lung Cancer Screening Market Revenue Forecast and Analysis
7. North America Lung Cancer Screening Market – Revenue and Forecast to 2028 – By Cancer Type
7.1 Overview
7.2 North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non–Small Cell Lung Cancer (NSCLC)
7.3.1 Overview
7.3.2 Non–Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Lung Cancer Screening Market Analysis – by Technology
8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
8.2.1 Overview
8.2.2 Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
8.3.1 Overview
8.3.2 Chest X-ray: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
8.4.1 Overview
8.4.2 Liquid Biopsy: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
9. North America Lung Cancer Screening Market Analysis – by Age Group
9.1 Overview
9.2 & Older
9.2.1 Overview
9.2.2 & Older: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
9.3.1 Overview
9.3.2 Below 50: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Lung Cancer Screening Market Analysis – by End User
10.1 Overview
10.2 Hospitals
10.2.1 Overview
10.2.2 Hospitals: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Lung Cancer Screening Market – Revenue and Forecast to 2028 – Country Analysis
11.1 North America Lung Cancer Screening Market Overview
11.1.1.1 US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.3 US: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.1.4 US: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.5 US: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.1.6 US: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.2 Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.3 Canada: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.2.4 Canada: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.5 Canada: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.2.6 Canada: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.3 Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.3 Mexico: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.3.4 Mexico: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.5 Mexico: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.3.6 Mexico: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
12. North America Lung Cancer Screening Market–Industry Landscape
12.1 Recent Growth Strategies
12.1.1 Overview
13. Company Profiles
13.1 Intelerad Medical Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Nuance Communications Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE HealthCare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medtronic
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Canon Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Koninklijke Philips NV
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CVS Health
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 bioAffinity Technologies, Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 LungLife AI, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About
14.2 Glossary of Terms

List of Tables

Table 1.             US North America Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 2.             US North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 3.             US North America Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 4.             US North America Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 5.             Canada North America Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 6.             Canada North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 7.             Canada North America Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 8.             Canada North America Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 9.             Mexico North America Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 10.          Mexico North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 11.          Mexico North America Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 12.          Mexico North America Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13.          Recent Growth Strategies in the North America Lung Cancer Screening Market
Table 14.          Glossary of Terms
 
 

List of Figures

Figure 1.           North America Lung Cancer Screening Market Segmentation
Figure 2.           North America Lung Cancer Screening Market, by Country
Figure 3.           North America Lung Cancer Screening Market Overview
Figure 4.           Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in North America Lung Cancer Screening Market
Figure 5.           North America Expected to Show Remarkable Growth During Forecast Period
Figure 6.           North America: PEST Analysis
Figure 7.           Experts’ Opinion
Figure 8.           North America Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9.           North America Lung Cancer Screening Market – Revenue Forecast and Analysis – 2020-2030
Figure 10.        North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11.        Non–Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12.        Small Cell Lung Cancer: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13.        North America Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14.        Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 15.        Chest X-ray: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 16.        Liquid Biopsy: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 17.        Others: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 18.        North America Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. & Older: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20.        Below 50: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21.        North America Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22.        Hospitals: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23.        Diagnostic Centers: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24.        Others: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25.        North America Lung Cancer Screening Market, by Key Country – Revenue (2022) (US$ Million)
Figure 26.        North America Lung Cancer Screening Market Revenue Share, by Key Country, (2022 & 2030)
Figure 27.        US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28.        Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29.        Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)

List of Companies

– bioAffinity Technologies, Inc
– Canon Medical Systems Corp
– CVS Health
– GE HealthCare Technologies Inc
– Intelerad Medical Systems Incorporated
– Koninklijke Philips NV
– LungLife AI, Inc
– Medtronic Plc
– Nuance Communications Inc
– Siemens AG

Reviews

There are no reviews yet.

Be the first to review “North America Lung Cancer Screening Market Forecast to 2030”